Exchange: NASDAQ·Updated 04:22 PM EST

MAZE News

News
all
press releases
Wall Street Analysts Predict a 93.92% Upside in Maze Therapeutics, Inc. (MAZE): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 93.9% in Maze Therapeutics, Inc. (MAZE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
Wall Street Analysts Predict a 93.92% Upside in Maze Therapeutics, Inc. (MAZE): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 93.9% in Maze Therapeutics, Inc. (MAZE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
More News
Maze Therapeutics, Inc. (MAZE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
The average of price targets set by Wall Street analysts indicates a potential upside of 123.4% in Maze Therapeutics, Inc. (MAZE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
Vertex on Tuesday announced results from the mid-stage trial of its experimental pill, inaxaplin, in two groups of patients with APOL1-mediated kidney disease.
Stocktwits
Key PointsChief Medical Officer Harold Bernstein sold 9,705 shares for ~$255,000 on September 4, 2026...
Nasdaq News: Markets
The consensus price target hints at a 120.5% upside potential for Maze Therapeutics, Inc. (MAZE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
Key PointsCEO Jason Coloma sold 27,858 shares for a total value of approximately $725,000 across June 22 and June 23, 2026...
Nasdaq News: Markets
Key PointsCEO Jason Coloma sold 32,564 shares in May for a total transaction value of approximately $847,000, at a weighted average price around $26.01 per share...
Nasdaq News: Markets
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares...
Yahoo! Finance: News
Maze Therapeutics, Inc. (MAZE) delivered earnings and revenue surprises of -5.07% and +23.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.